| Autor: |
Stacy ZA; St. Louis College of Pharmacy, Cardiology, Mercy Hospital St. Louis, St. Louis, MO, USA. zstacy@stlcop.edu., Call WB; St. Louis College of Pharmacy, Internal Medicine, Barnes-Jewish Hospital, St. Louis, MO, USA., Hartmann AP; St. Louis College of Pharmacy, Internal Medicine, Barnes-Jewish Hospital, St. Louis, MO, USA., Peters GL; St. Louis College of Pharmacy, Internal Medicine, Barnes-Jewish Hospital, St. Louis, MO, USA., Richter SK; St. Louis College of Pharmacy, Ambulatory Care, VA St. Louis Health Care System-John Cochran Division, St. Louis, MO, USA. |
| Abstrakt: |
Historically, vitamin K antagonists have been the only class of oral anticoagulants available. Despite our experience with warfarin over the past 60 years, its use is associated with several pharmacokinetic and clinical disadvantages including unpredictable dosing, frequent monitoring, and delayed onset and offset. Edoxaban, an oral direct Xa inhibitor, may provide clinicians with an additional option in patients requiring chronic anticoagulation. This review examines the pharmacology and clinical data of edoxaban as a therapeutic alternative. |
